The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO– ESGO consensus conference on ovarian cancer was held on 12–14 April 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relev...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Objective: The aim of this study was to develop clinically relevant and evidence-based guidelines as...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines is one of the core activities of the European Society for Medical Onco...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines is one of the core activities of the European Society for Medical Onco...
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & On...
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy &...
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy &...
Objective The aim of this study was to develop clinically relevant and evidence-based guidelines as ...
In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO...
Recently, ovarian cancer research has evolved considerably because of the emerging recognition that ...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Objective: The aim of this study was to develop clinically relevant and evidence-based guidelines as...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines is one of the core activities of the European Society for Medical Onco...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines recommendations is one of the core activities of the European Society ...
The development of guidelines is one of the core activities of the European Society for Medical Onco...
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & On...
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy &...
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy &...
Objective The aim of this study was to develop clinically relevant and evidence-based guidelines as ...
In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO...
Recently, ovarian cancer research has evolved considerably because of the emerging recognition that ...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
Objective: The aim of this study was to develop clinically relevant and evidence-based guidelines as...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...